secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001641172-25-015346
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3
--------------------------------------------------------------------------------

- Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
- Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.
- Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.
- Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.
- If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer